Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Gojo

Showing results (91-100 of 122) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2018
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJason Gotlib, Aaron T Gerds, Prithviraj Bose, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Blood Advances|May 20, 2026
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated diseaseNour Sabiha Naji, Taha Soueidatt Ahmedna, Xinghan Zeng, et al.
Transplantation and Cellular Therapy|February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for MyelofibrosisTania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Blood Advances|October 15, 2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AMLJayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Pageof 13

Showing results (91-100 of 122) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2018
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent FailureAmer M Zeidan, Hanna A Knaus, Tara M Robinson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2016
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic LeukemiaKeith W Pratz, Michelle A Rudek, Ivana Gojo, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 9, 2021
Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center ExperienceAlexander Ambinder, Matthew Smith, Hua-Ling Tsai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2018
Systemic Mastocytosis, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJason Gotlib, Aaron T Gerds, Prithviraj Bose, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 14, 2016
Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in OncologyRuben Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Blood Advances|May 20, 2026
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated diseaseNour Sabiha Naji, Taha Soueidatt Ahmedna, Xinghan Zeng, et al.
Transplantation and Cellular Therapy|February 14, 2022
Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for MyelofibrosisTania Jain, Hua-Ling Tsai, Amy E DeZern, et al.
Blood|October 16, 2014
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDSChristopher G Kanakry, Hua-Ling Tsai, Javier Bolaños-Meade, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Blood Advances|October 15, 2020
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AMLJayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, et al.
Pageof 13